Johnson & Johnson (JNJ) is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson is headquartered in New Brunswick, New Jersey, directly adjacent to the campus of Rutgers University, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in over 57 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $65 billion for the calendar year of 2011. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses.
FDA approves 1st cheaper version of J&J's top drug Remicade WASHINGTON — Federal health officials have approved a cheaper version of Johnson & Johnson's (JNJ) blockbuster drug, Remicade, a pricey biotech medicine for inflammatory diseases. The approval of Inflectra Tuesday is only the second time that the Food and Drug Administration has approved a quasi-generic biotech drug for the U.S. market. These so-called biosimilar drugs, already available in Europe, have the potential to generate billions of dollars in savings for insurers, doctors and patients in coming years. Inflectra, from drugmakers Celltrion and Pfizer (PFE), is approved for a half-dozen uses, including psoriasis and five other conditions in which the immune system attacks the body's tissue. The drug helps reduce inflammation and control the immune system, which helps slow those diseases. Remicade, first approved in 1998, is J&J's top-selling medicine with sales of $6.56 billion last year. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2014, the latest year data is available, six of the 10 best-selling medicines globally were biologics, with about $49 billion in combined sales. For decades, biotech drugs lacked generic competition because the FDA had no system to approve cheaper versions. That changed in 2012 and the agency approved the first biosimilar drug last March — a cheaper version of the blockbuster Amgen drug Neupogen. Biosimilar is the industry term for generic biotech drugs, used to indicate that they are not exact copies of the original biologic medicines. "Biosimilars can provide access to important treatment options for patients who need them," said Janet Woodcock, the FDA's director for drugs. Remicade sales slipped 4 percent in 2015 due to overseas competition from biosimilar versions already made by Pfizer and Celltrion Inc., which is based in South Korea. New York-based Pfizer will market Inflectra in the U.S. The company said it plans to launch the drug in 2016 but declined to comment on its price. "Each biosimilar molecule has specific drivers that determine market price," the company said in an emailed statement. Pfizer shares rose 64 cents, or 2 percent, to close at $31.36 in trading Tuesday. A key factor in U.S. uptake of the new drug will depend on whether it is reserved for first-time patients or whether patients already on Remicade are switched to the cheaper medication. Many states are still deciding whether pharmacists can substitute a biosimilar for the original biologic drug without the prescribing doctor's permission, as usually happens with generic pills. Other blockbuster biotech drugs expected to face U.S. competition in coming years include AbbVie's anti-inflammatory drug Humira, which is from the same family as Remicade. Humira was the best-selling drug in the world last year with sales of $14 billion.
Johnson & Johnson shares rise on higher Q1 results Johnson & Johnson stock closed 1.58% higher at $112.68 a share. The company's adjusted diluted earnings per share for the quarter came in at $1.68, above the $1.65 consensus forecast of analysts surveyed by S&P Global Market Intelligence. Johnson & Johnson said its quarterly revenue was $17.48 billion, nearly matching the $17.491 billion prediction of Wall Street analysts. Johnson & Johnson raised its sales guidance for the full year to $71.2 billion to $71.9 billion, reflecting expectations of improved foreign currency exchange rates. The company had predicted full-year sales of $70.8 billion to $71.5 billion three months ago. Similarly, the firm increased its adjusted full-year earnings guidance to $6.53-$6.68 a share, up from earlier forecasts of $6.43 to $6.58. Read full article here: http://www.usatoday.com/story/money/2016/04/19/johnson--johnson-q1-earnings/83221304/
Reported before open today (7/19/16) Earnings: EPS $1.74 Revenue $18.5B Estimates: EPS $1.67 Revenue $17.9B Up 2.12% pre-market so far
The stock has room up to $127.50 on continued market strength. Price needs to hold $109.00 through year end to validate this years move and offer a possible extension into next year. Only a trade below $103.50 jeprodizes the recent extent of the rally. Another candidate worthy of a long term hold.
Q3 ER Estimates: Earnings Whisper: $1.66 Consensus: $1.65 Revenue: $17.69 Bil Date & Time of ER: Tuesday Oct 18 6:40 AM ET
Reported before open today (10/18/16) Earnings: EPS $1.68 Revenue $17.8B Estimates: EPS $1.65 Revenue $17.71B Down 2.60% today
Upcoming dividend information: Ex-Div-Date: 11/18/16 Payment Date: 12/6/16 Dividend: $0.80 Current Price: $118.47 Annual Yield: 2.70%
J&J said to make approach for $17 billion Swiss biotech Actelion. shares up of Actelion. $JNJbloomberg.com/news/articles...
Johnson & Johnson beats by $0.02, misses on revenue Revenue of $18.11B (+1.7% Y/Y) misses by $170M. Shares -1.15% PM.
New competition took a bite out ofJ&J's drug sales, but don't expect the trend to dominate this earnings period $JNJ http://tinyurl.com/gvjvczo
Johnson & Johnson ($JNJ) reported better than expected first quarter earnings, although the healthcare giant’s revenues came in below expectations. The company still raised its full-year earnings and revenue outlook.
This news was out midday and had no effect on price. One of the few green today. Priced in and new ATH's this week.
When a stock breaks out of a base on huge bullish volume and an ER beat and guidance raise, that's when you buy more!
JNJ will likely announce their next quarterly dividend sometime next week, and as a long-time Dividend Aristocrat it is due to announce a raise. It currently pays .84 per quarter and yields around 2.5% and over time JNJ's price has appreciated in lockstep with the dividend: During the past year, JNJ dividend announcements appear to correlate fairly well with some price appreciation, either before, after, or both before and after the announcement. The following chart shows price run-ups and/or bumps around the timing of divy announcements [inside the purple boxes]: With a decent earnings announcement this morning that included raising their 2018 year-end guidance, this might be a good time to purchase a couple shares for grins.
I like JNJ products. From Yahoo Finance, it expects Johnson & Johnson JNJ, a healthcare bellwether, to beat expectations when it reports first-quarter 2018 results on April 17, before market opens.
This is a really cheap company but few investors are willing to buy it because it doesn't have much growth. I will never understand why. Last year they completed the purchase for Actelion for $30B, at no added cost, that brought a few cost synergies with the deal yet investors shunned it since it barely moved the needle on growth. Why not view it through the opportunity this generates the company into the biotechnology space? As long as $122.30 - $123.12 holds into Labor Day, it has legs up to $127.33 and possibly as high as $133.50 to $136.50. February - March points to an important date in time. A break below this price point speaks of a broader break in confidence in the stock market. Large cap companies like JNJ break first before the broader market does.
